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Abstract
Background: Intermittent preventive treatment (IPT) of malaria involves administration of curative doses of antimalarials at
specified time points to vulnerable populations in endemic areas, regardless whether a subject is known to be infected. The
effect of this new intervention on the development and maintenance of protective immunity needs further understanding.
We have investigated how seasonal IPT affects the genetic diversity of Plasmodium falciparum infections and the risk of
subsequent clinical malaria.
Material and Methods: The study included 2227 Ghanaian children (3–59 months) who were given sulphadoxine-
pyrimethamine (SP) bimonthly, artesunate plus amodiaquine (AS+AQ) monthly or bimonthly, or placebo monthly for six
months spanning the malaria transmission season. Blood samples collected at three post-interventional surveys were
analysed by genotyping of the polymorphic merozoite surface protein 2 gene. Malaria morbidity and anaemia was
monitored during 12 months follow-up.
Results: Monthly IPT with AS+AQ resulted in a marked reduction in number of concurrent clones and only children parasite
negative just after the intervention period developed clinical malaria during follow-up. In the placebo group, children
without parasites as well as those infected with $2 clones had a reduced risk of subsequent malaria. The bimonthly SP or
AS+AQ groups had similar number of clones as placebo after intervention; however, diversity and parasite negativity did not
predict the risk of malaria. An interaction effect showed that multiclonal infections were only associated with protection in
children without intermittent treatment.
Conclusion: Molecular typing revealed effects of the intervention not detected by ordinary microscopy. Effective seasonal
IPT temporarily reduced the prevalence and genetic diversity of P. falciparum infections. The reduced risk of malaria in
children with multiclonal infections only seen in untreated children suggests that persistence of antigenically diverse P.
falciparum infections is important for the maintenance of protective malaria immunity in high transmission settings.
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Introduction
Malaria is one of the most severe infectious diseases. Despite
recent reports of decreasing incidence in some areas, infection by
Plasmodium falciparum remains a major threat to health and
economic development in Sub-Saharan Africa [1]. Children
under five years of age and pregnant women are at highest risk
of disease and death. Control strategies targeting these groups are,
therefore, of high priority. A new strategy to control malaria is
intermittent preventive treatment (IPT), which involves adminis-
tration of therapeutic doses of anti-malarial drugs at specified time
points regardless whether a subject is known to be infected. IPT is
a modification of previously used chemoprophylaxis which was not
considered to be sustainable due to logistic difficulties, concerns
over the emergence of drug resistant parasites and impaired
development of malaria immunity. The advantage of intermittent
treatment over sustained chemoprophylaxis is reduced drug
exposure. The intervention is implemented in pregnant women
(IPTp), reducing anaemia in the mother and increasing birth
weight of the child [2]. Several studies of IPT in infants (IPTi) with
sulphadoxine-pyrimethamine (SP) given at the age of 2, 3 and 9
months alongside the extended program on immunization have
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13649shown a reduction in the incidence of clinical malaria and
anaemia by about 30% [3] and IPTi is now recommended for
implementation in areas with high burden of malaria and low SP
resistance [4].
IPTi is likely to be most effective in areas with continuous high
malaria transmission. However, in many areas of sub-Saharan
Africa, especially those with seasonal transmission, the main
burden of malaria is in older children. An alternative approach in
these areas is administration of IPT to children (IPTc) during the
high transmission season. Seasonal IPT reduced the incidence of
clinical malaria by 17–86% depending on antimalarial drug and
dosage regime [5,6].
Some rebound in malaria morbidity was reported following
sustained chemoprophylaxis [7,8] and some IPT studies have
reported increased incidence of clinical malaria or anaemia in sub-
groups of subjects when the intervention was stopped [9,10,11]. In
spite of these reports, a meta-analysis of all the published trials of
IPTi did not find any evidence that IPT leads to rebound of
malaria in infants [3]. Whether intermittent treatment affects
immunity towards malaria when given as seasonal intervention
and in older children who have acquired partial protection is
however unclear.
In high transmission areas, immunity to malaria develops
gradually following repeated exposure and P. falciparum infections
are often composed of multiple genetically distinct clones. The
ability to control diverse infections may be a key feature of
protective immunity. The number of clones correlates with
transmission intensity and age [12,13,14,15]. In areas of intense
transmission, asymptomatic multiclonal infections have been
associated with a reduced risk of subsequent clinical malaria in
partially immune children [16,17], whereas in young children and
in moderate to low transmission settings, a high number of clones
appears to be a risk factor for disease [18,19,20]. The number of
clones thus appears to be a marker of exposure and immunity.
Persistence of low density infections composed of antigenically
diverse parasites may per se be important to maintain protection in
areas of intense transmission. For these reasons we have
investigated how intermittent treatment affects subsequent P.
falciparum infections and risk of clinical malaria and anaemia within
a seasonal IPT trial in Ghanaian children [10].
Materials and Methods
Study site
A randomized, placebo-controlled IPTc trial was conducted in
Hohoe district, Ghana during 2005 to 2006 [10]. Malaria is
endemic in the area with peak transmission following the rainy
seasons in April to July and September to November, with an
estimated transmission intensity of ,65 infective bites/person/
year [10]. Written consent was obtained from the caretakers of
participating children. Ethical approval was granted by the Ghana
Health Services/Ministry of Health, London School of Hygiene
and Tropical Medicine Ethics Committee and the Regional
Ethical Review Board in Stockholm, Sweden.
Study outline
In total 2227 of the 2451 participating children (aged 3 to 59
months), provided comprehensive data required for this study.
The IPTc trial has been described in detail elsewhere [10]. In
brief, enrolled children were allocated to either treatment regimen;
SP bimonthly (every second month), AS +AQ bimonthly, AS +AQ
monthly, or a placebo monthly, given over a six month period of
intense malaria transmission (Figure 1). A drug simulating placebo
was given on alternate months in the bimonthly groups. During
the intervention period, children were visited weekly at their
homes for health assessment. The parents were advised to take the
child to the health facility for examination and treatment if the
child had a history of fever of vomiting within the past 48 hours.
Three cross-sectional surveys were performed during the 12
months follow-up in addition to passive surveillance for clinical
malaria and anaemia at the study hospital.
Clinical case definitions
A clinical episode of malaria was defined as fever (axillary
temperature $37.5u C or reported fever within the past 48 hours)
together with any P. falciparum parasiteamia detected by micros-
Figure1. Study outline. Intermittent preventive treatment or placebo was givenover a sixmonth-period spanning peak malariatransmission season,
followedbya12-monthpostinterventionsurveillanceperiod.Cross-sectionalsurveyswereperformed1 month(November2005),6 months(April2006)
and 12 months (November 2006) after the intervention was stopped. Blood films and filter paper samples were collected at these three time points.
doi:10.1371/journal.pone.0013649.g001
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and a peripheral parasiteamia of .7000 parasites/ml blood, a local
threshold with high specificity for clinical malaria [10]. All malaria
episodes were treated with oral quinine for seven days according to
national guidelines. Anaemia was defined as a haemoglobin (Hb)
concentration less than 8 g/dl blood [10].
Cross sectional surveys and sample collection
Initial screening for eligibility was performed one month before
administration of the first IPT dose (May 2005). After the six-
month intervention period (June-October 2005), three cross-
sectional surveys were performed: 1) at the end of the intervention
period (November 2005); 2) at the end of following dry season,
(April 2006); and 3) at the end of the following rainy season
(November 2006) (Figure 1). Axillary temperature and Hb
concentration were measured at all surveys. Blood films and filter
paper (Grade 541, Whatman) samples were collected at the three
cross-sectional surveys, however not at the initial screening.
Parasites were counted by light microscopy against 200 leukocytes
and converted to parasites/ml following the assumption of 8000
leukocytes/ml blood. Filter papers were stored in individual plastic
bags at room temperature.
Genotyping of msp2
Filter paper samples from microscopy positive children collected
at the three cross-sectional surveys were all analyzed by msp2
genotyping. DNA was extracted from whole blood spots on filter
paper using ABI Prism 6100 Nucleic Acid PrepStation (Applied
Biosystems). P. falciparum infections were characterized by
genotyping of the merozoite surface protein 2 (msp2) gene using
fluorescent PCR and capillary electrophoresis (CE) [21]. In brief,
in the primary PCR, oligonucleotide primers span the outer region
of msp2 (block 3) followed by separate, nested reactions with
fluorescently labeled primers distinguishing the respective allelic
types of msp2, FC27 and IC. CE was performed on a 3730 DNA
sequencer using GeneMapperH Software (v 4.0) (both Applied
Biosystems). A cut off of 300 relative fluorescent units was used to
distinguish true alleles from non-specific low artefact peaks [21].
Statistical methods
Data analysis was performed using R (v 2.9.0) and SPSS (v 17).
Comparisons of parasite prevalence between treatment groups
were assessed by Chi-square tests. Associations between the
number of clones and parasite densities were analysed by
Spearman rank. The presence of high number of clones i.e. $3
were compared between the groups by Fisher’s exact test. When
used as explanatory variable, the number of msp2 clones was
categorised to avoid assumptions about linearity as follows: 0 i.e.
negative by microscopy, 1 and $2 clones. Age was grouped into
five categories (3–11, 12–23, 24–35, 36–47 and 48–59 months)
and parasite densities into quartiles. Association between number
of clones and treatment group, age, parasite densities, sex and
clinical malaria during intervention (yes/no) was assessed by
logistic regression (with clones as outcome comparing 1 with $2
clones). Association between number of clones and anaemia
(Hb,8.0 g/dl) (with anaemia yes/no as outcome) at the respective
surveys was analyzed by logistic regression.
The prospective risk of clinical malaria was assessed by Cox
regression analysis based on time to first or only clinical episode
during the 12-month follow-up. The analysis included children who
participated in the first post-intervention survey, with one or two
subsequent samples.Analysiswas performed for all children and then
per separate treatment group. The data on clones, age and parasite
densities was categorised as described above. To identify strictly
asymptomatic individuals, children with clinical episode during the
period 28 daysbeforeuntil7days after survey wereexcluded fromthe
survival analyses since number of clones can be affected by clinical
episode or recent treatment [22,23]. Hazard ratios (HR) were
assessed in a model including number of msp2 clones (0, 1 and $2),
sex, age, owning a bednet, treatment group and clinical malaria (yes/
no) duringtheintervention period.Bothclinicaldefinitionsof malaria
(see above) were used in the risk assessments. When the more strict
definitionofmalaria(fever and .7000parasites/ml)wasused, 28days
weresubtractedfromthetimeatriskifchildrenhadbeentreatedwith
quinine due to a clinical episode with fever and ,7000 parasites/ml.
The proportional hazards assumption was assessed using tests and
graphical diagnostics based on scaled Schoenfeld residuals. Unad-
justed Kaplan Meier survival plots with time to a first clinical episode
ofmalariaweremade forallchildrenand fortheindividualtreatment
groups, respectively.
Results
Parasite prevalence post intervention
At the first survey after the intervention was stopped, the
prevalence of P. falciparum infection by microscopy was lower
(5.2%) in children who had received monthly AS+AQ treatment
compared to children given placebo (19.8%) (p,0.05, Chi-square,
Table 1). There was however no difference in parasite prevalence
in the bimonthly SP or AS+AQ group compared to the placebo
group. Six months post-intervention, at the end of the following
dry season, the prevalence was low in all groups although relatively
higher in children who had received IPT (Table 1). At the
following rainy season, 12 months post-intervention, parasite
prevalence was similar in all groups. There were no differences in
parasite densities between the groups except for the SP group in
which densities were higher at the two first surveys (Table 1).
Msp2 diversity post intervention
One month after the intervention at the first survey, multiclonal
infections ($2 clones), were detected in 60.6–70.1% of the PCR
positive samples from asymptomatic children. Children in the
AS+AQ monthly group were infected with 1–2 clones (Figure 2), a
significantly higher proportion of children with 3 or more clones
were found in the placebo group where up to 8 clones were
detected (p=0.009, Fisher’s exact test). No such differences were
detected comparing the bimonthly groups to placebo. There was a
weak correlation between number of clones and parasite densities
using continuous data r=0.20 (p=0.043, Spearman rank). Age was
associated with diversity only in the placebo group where children
older than 11 months were more likely to be infected with $2
clones than younger children [OR 7.73, 95% CI 1.49–60.50], a
difference that persisted after adjusting for parasite density and
owning a bednet. Six and 12 months after the intervention, the
number of clones was equally high in all groups (Figure 2).
Msp2 diversity and anaemia
Children with parasites were more likely to be anaemic than
children without parasites [OR 2.65, 95% CI 1.91–3.68, adjusted
for age, clinical episode during intervention and treatment group].
Multiple clones did not increase the likelihood of aneamia
compared to single clone infection [OR 1.67, 95% CI 0.87–
3.36; adjusted as above].
Msp2 diversity and risk of clinical malaria
During the intervention period, children receiving active treat-
ment,especiallywithmonthlyAS+AQ, experienced fewer episodes of
malaria than children given placebo [10]. During the 12 months
Malaria IPT and Diversity
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placebo group; 82 in the SP bimonthly group; 64 in the AS+AQ
bimonthly group and 83 in the AS+AQ monthly group. Episodes
with high density parasitaemia (.7000 parasites/ml) were reported in
185 episodes; 32 in the placebo group; 52 in the SP bimonthly group;
44 in the AS+AQ bimonthly group and 57 in the AS+AQ monthly
group. Within the AS+AQ monthly group, only children who were
parasite negative at the first survey after the intervention period
developed clinical malaria during follow up. The risk of clinical
malaria during follow-up was significantly higher among children
given IPTwithmonthlyAS+AQcompared to childrengiven placebo
[HR 1.55, 95% CI 1.05–2.27] while therewas a tendency towards an
increased risk among children in the SP bimonthly group [HR 1.36
95% CI0.94–2.10] and the AS+AQ bimonthly group [HR1.20 95%
CI 0.78–1.83]. Similar results were seen using the more strict
definition of malaria (.7000 parasites/ml).
Univariate time to event analysis including all asymptomatic
children (n=1856), showed that multiclonal infections were,
compared to single clone infections, associated with a reduced risk
of subsequent malaria using both clinical definitions (Table 2). The
risk of malaria decreased with age and was highest in children who
received AS+AQ monthly, and were ,11 months when they
received their first IPT dose. Parasite status (positive or negative),
parasite density, sex, owning a bednet and clinical malaria during the
intervention period were not associated with prospective malaria risk.
In a multivariate analysis including all asymptomatic children
and adjusting for age and treatment group, the decreased risk of
disease in children with multiclonal infections at baseline remained
significant for both malaria definitions (Table 2/Figure 3). The
association with protection was significant in the placebo group
(Table 2/Figure 4A). Moreover, parasite negative children also
had a decreased risk of disease compared to those with a single
clone. A similar, non-significant trend was seen in the AS+AQ
bimonthly group (Table 2/Figure 4C), whereas no such
association was found in the SP group (Table 2/Figure 4B). In
the AS+AQ monthly group, analysis regarding number of clones
was not possible since none of the children with parasites at
baseline developed clinical malaria during follow up (Figure 4D).
Table 1. Parasitological findings at three cross-sectional surveys following a 6 months intervention period with different IPT
regimes.
Characteristics Placebo
SP
bimonthly
AS+AQ
bimonthly
AS+AQ
monthly
All Asympt
a All Asympt
a All Asympt
a All Asympt
a
After the intervention
period (n)
591 579 555 541 502 476 579 573
Any parasiteamia
b (%) 19.8 19.0 17.5 16.1 20.5 18.3 5.2* 4.9*
Parasitaemia
b.7000/ml (%) 6.9 6.7 7.9 6.8 8.2 6.3 1.6* 1.6*
Parasite density
(geometric mean, (range))
2516
(40–68440)
2465
(40–68440)
4754
(80–180800)
4014
(80–92800)
3290
(80–213240)
2517
(80–213240)
1889
(80–115320)
2010
(80–115320)
msp2 diversity (median, (range)) 2 (1–8) 2 (1–8) 2 (1–5) 2 (1–5) 2 (1–6) 2 (1–6) 2 (1–2) 2 (1–2)
.1 msp2 clone (%) 70.6 70.1 67.4 70.1 60.5 60.6 66.7 69.2
$3 msp2 clones (%) 36.3 36.1 32.6 32.5 29.8 28.2 0 0
Post intervention dry
season (n)
481 476 442 436 403 400 463 456
Any parasitaemia
b (%) 6.7 6.1 10.6* 9.9* 10.0 9.5 11.2* 10.3*
Parasitaemia
b.7000/ml (%) 2.1 1.5 4.5* 4.1* 2.5 2.5 3.2 2.6
Parasite density
(geometric mean, (range))
2112
(120–121600)
1619
(120–89600)
4529
(240–162240)
4719
(240–162240)
1776
(120–140000)
1825
(120–140000)
2926
(80–168800)
2615
(80–168800)
msp2 diversity (median, (range)) 2 (1–6) 2 (1–6) 2 (1–4) 2 (1–4) 2 (1–6) 2 (1–6) 2 (1–5) 2 (1–5)
.1 msp2 clone (%) 50.0 50.0 55.0 54.1 69.0 67.9 54.3 53.7
$3 msp2 clones (%) 29.2 31.8 25.0 24.3 24.3 25.0 23.9 22.0
Post intervention rainy
season (n)
448 434 401 392 363 357 430 419
Any parasitaemia
b (%) 37.3 35.5 36.4 35.5 38.0 37.3 41.2 39.9
Parasitaemia
b .7000/ml (%) 8.9 8.3 7.5 6.9 8.8 8.1 10.2 8.8
Parasite density
(geometric mean, (range))
2249
(40–172480)
2231
(40–172480)
2187
(40–162240)
2003
(40–162240)
2399
(40–169240)
2214
(40–141360)
2223
(40–332960)
1995
(40–332960)
msp2 diversity (median, (range)) 2 (1–8) 2 (1–7) 2 (1–6) 2 (1–6) 2 (1–6) 2 (1–6) 2 (1–7) 2 (1–7)
.1 msp2 clone (%) 74.8 75.2 72.9 72.3 74.5 74.7 71.7 70.6
$3 msp2 clones (%) 43.7 44.0 44.9 44.6 44.1 43.4 44.1 43.7
These parasitological data have been presented previously [10]. The prevalence figures presented here differ slightly from those in the previous publication because it
was not possible to obtain data on parasite genotype for all the children in the study due to missing samples.
aExcluding children with clinical malaria at survey, 28 days before and 7 days after.
bDetermined by microscopy.
*compared to the placebo group p,0.05 (Chi-square).
doi:10.1371/journal.pone.0013649.t001
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genotypes at the respective surveys; 1 month after the intervention, at the following dry season 6 months post-intervention, and
at the end of the following rainy season 12 months post-intervention. The number within brackets in Figure 2a represents the total number
of children in the respective groups.
doi:10.1371/journal.pone.0013649.g002
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could have been due to the relatively few parasite positive children.
An analysis investigating the interaction between treatment/
placebo and protective effect of $2 clones was therefore conducted.
In an analysis comparing groups with similar diversity after ended
intervention i.e. placebo and the bimonthly IPT groups (SP and
AS+AQ) an interaction between infection diversity and treatment
showed that the protective effect of having $2 clones was
significantly higher in children with placebo compared to children
who had received bimonthly IPT [HR 0.092, 95% CI 0.009–0.980]
The pointestimatesindicated that the protectiveeffectofhaving $2
clones was relatively strong, reducing the risk by a factor of ten.
Discussion
Intermittent treatment administered during the intense malaria
transmission season affected the diversity of P. falciparum infections,
defined by msp2 genotyping, and its relation to the subsequent risk
of clinical malaria in these children in Hohoe District in Ghana.
During the 6 months intervention period, the incidence of clinical
malaria and anaemia was substantially reduced [10]. Here, we
present genotyping and clinical data from the 12-months follow-up
after ended intervention.
With the most intense regime of monthly AS+AQ, the
prevalence and diversity of P. falciparum infections was clearly
reduced in the first survey one month after the intervention, with
detection of only 1–2 clones compared to up to 6–8 clones in the
other groups. This reduction was, however, only temporary and
there was no difference between the groups 6 and 12 months later.
Interestingly, there was a distinct difference depending on whether
AS+AQ had been administered monthly (6 courses) or bimonthly
(3 courses), with the last effective course one and two months
before the first post-intervention survey respectively. After just one
additional month, there was no difference in the number of
Table 2. Risk for subsequent clinical malaria in asymptomatic children (n=1856) during the 12 months follow up after the
intervention.
All episodes
High parasite density episodes
(.7000 parasites/ml)
HR
unadjusted
(95% CI)
HR
adjusted
a
(95% CI)
HR
adjusted
b
(95% CI)
HR
unadjusted
(95% CI)
HR
adjusted
a
(95% CI)
HR
adjusted
b
(95% CI)
Total
msp 2 clones
0 0.66
(0.37–1.19)
0.67
(0.37–1.20)
0.62
(0.34–1.12)
0.61
(0.31–1.20)
0.61
(0.31–1.21)
0.56
(0.28–1.11)
1
* 1.00 1.00 1.00 1.00 1.00 1.00
$2 0.39
(0.17–0.91)
0.43
(0.19–0.99)
0.43
(0.19–0.99)
0.32
(0.11–0.90)
0.36
(0.13–1.01)
0.35
(0.13–1.00)
Placebo
msp 2 clones
0 0.36
(0.15–0.85)
0.30
(0.12–0.73)
NA 0.34
(0.19–0.99)
0.31
(0.10–1.002)
NA
1
* 1.00 1.00 1.00 1.00 1.00 1.00
$2 0.07
(0.0084–0.58)
0.066
(0.0078–0.56)
NA 0.11
(0.012–0.99)
0.17
(0.01–1.14)
NA
SP bimonthly
msp 2 clones
0 1.26
(0.31–5.20)
1.30
(0.31–5.38)
NA 0.87
(0.21–3.59)
0.93
(0.23–3.76)
NA
1
* 1.00 1.00 1.00 1.00 1.00 1.00
$2 1.11
(0.22–5.72)
1.23
(0.24–6.43)
NA 0.44
(0.06–3.06)
0.50
(0.07–3.41)
NA
AS+AQ bimonthly
msp 2 clones
0 0.53
(0.19–1.51)
0.53
(0.19–1.49)
NA 0.51
(0.16–1.66)
0.51
(0.15–1.71)
NA
1
* 1.00 1.00 1.00 1.00 1.00 1.00
$2 0.58
(0.14–2.31)
0.57
(0.14–2.30)
NA 0.59
(0.12–2.86)
0.58
(0.11–2.98)
NA
The AS+AQ monthly group is not included in the table since no parasite positive children developed a clinical episode during follow up.
*reference group.
aadjusted for age.
badjusted for age and treatment group.
NA not applicable.
No significant deviations from the proportional hazards assumptions were found.
doi:10.1371/journal.pone.0013649.t002
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suggesting that multiclonal infections are rapidly accumulated in
this setting.
In the monthly AS+AQ group, only children who were parasite
negative at the first survey after intervention developed clinical
malaria during follow-up. In the placebo group parasite negative
children were at lower risk of subsequent malaria, whereas no
significant risk was detected in the bimonthly groups. These
parasite negative children might both represent a group with lower
exposure as well as children with efficient immunity. Notably, this
reduced risk was only seen in the untreated children.
When assessing whether the number of clones in asymptomatic
P. falciparum infections predicted the subsequent risk of malaria,
infections with $2 clones were associated with a reduced risk in
the placebo group, representing the natural condition in this
setting. Interestingly, children in the bimonthly IPT groups were
infected with similar number of clones as children receiving
placebo, and although there was a tendency in the AS+AQ
bimonthly group, clones did not confer protection in neither of
these two groups. The protective effect of multiclonal infections in
the placebo group was, indeed, relatively strong reducing the risk
by a factor of ten compared to the bimonthly IPT groups. This
suggests that it is not only the number of clones present at a single
time point, but infections over a preceding period that influence
malaria immunity.
Asymptomatic multiclonal P. falciparum infections have previ-
ously been associated with a reduced subsequent risk of clinical
malaria in high transmission areas [16,17,24,25]. The opposite
was, however, found in low transmission settings, suggesting an
exposure dependent component [18,19,20]. Considering the short
half-life of malaria specific antibody responses [26] we have
hypothesized that multiclonal infections per se are important in
stimulating protective immunity. Reduced levels of anti-P.
falciparum IgG antibodies have been reported after sustained
chemoprophylaxis [27] as well as after single-dose SP treatment
within an IPTi trial [28]. Parasite prevalence was not associated
with subsequent risk of clinical malaria in the current study;
instead a reduced risk was associated with diversity of infections
among untreated children. This supports the notion that persistent
infections composed of antigenically different clones are important
for protection.
The effect on malaria risk was most pronounced at the
beginning of the following rainy season when the number of
clinical episodes increased (Figure 3). The low parasite prevalence
at the dry season survey, however, precluded this as baseline for
prospective risk analysis. Although parasite prevalence was low,
more than 50% of the infections detected at the dry season survey
were composed of multiple clones. The ability among untreated
children to control new infections as the transmission season starts
might be due to low-level multiclonal infections that persisted
throughout the dry season [29,30], while previously treated
children were more susceptible to disease when infected with
novel parasite clones [12]. This is supported here by the finding
that parasite negativity conferred protection only in children in the
placebo group and not in the treatment groups.
A limitation of the current study is that blood samples were not
collected before IPT was given. Such samples would have further
elucidated the effect of IPT on infection diversity in the respective
treatment groups and would have provided information on
whether children attain the same diversity after a six months
intervention period, i.e. reflecting tolerance to certain levels of
diversity. Moreover, parasite prevalence and infection diversity is
likely to have been underestimated since only filter paper samples
from microscopy positive children were available for genotyping.
Analyses of all children by PCR would have allowed for a more
correct and in depth analyses of parasite positivity and diversity
since the method generally detects a larger proportion of
parasitized individuals in endemic settings compared to micros-
copy. This would also have given the opportunity to identify
continuously parasite negative individuals who could be regarded
as unexposed and excluded in a separate risk analysis.
Children who received placebo experienced more clinical
episodes of malaria during the intervention period [10]. Quinine,
the drug used for treatment, has a short half-life and would not be
expected to have any prophylactic effect. There was no difference
in the number of clones after intervention whether the children
had been treated or not during the six months intervention so
different levels of prior treatment are not likely to have been a
confounding factor.
The parasitological failure rate was 2.3% for AS+AQ and 6.8%
for SP, and the re-infection rates at day 28 was 16% for AS+AQ
and 19% for SP in the original IPTc study [10], suggesting that the
drugs were efficacious. The relatively low drug resistance in the
area is therefore not likely to have had a substantial effect on the
diversity of infections or malaria morbidity.
Seasonal IPT reduced the prevalence of anemia by 30–45%,
but with no prolonged effect beyond the intervention period [10].
Parasite prevalence was associated with anaemia after ended
intervention; however multiclonal infections were not associated
with increased likelihood of being anaemic. This suggests that
malaria anaemia is more likely influenced by high parasite loads
than by the genetic diversity of infections.
The risk of clinical malaria during follow up was increased in
infants (3–11 months) given monthly AS+AQ, and there was a
tendency in this direction in the bimonthly treatment groups. A
similar rebound in morbidity in infants given IPT was suggested in
another high transmission setting in Ghana [9]. A meta-analysis of
IPTi studies did not show a rebound in malaria morbidity after
ended intervention [3]. The concept of IPTi with antimalarial
treatment given at the time of routine immunization the first year
Figure 3. Kaplan Meier estimate (unadjusted) of time to
subsequent clinical episode (fever and any P. falciparum)i n
1856 asymptomatic children.
doi:10.1371/journal.pone.0013649.g003
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present study where drugs are given repeatedly during the intense
transmission season. The effect of IPT in infants is likely to be
mainly prophylactic, preventing rather than clearing present
infections. In older children, with partial immunity and often
asymptomatic infections, the clearance of parasites might also be
important. The reduced exposure to multiclonal infections
achieved by seasonal IPT might affect immunity and explain the
rebound in morbidity seen after IPT in some studies. Current
recommendations for IPTi with SP state that the intervention
should be implemented only in areas with moderate to high
transmission [4]. Seasonal IPT might indeed have different effects
in different transmission settings and age groups.
In conclusion, our findings show that seasonal IPT in children
under five affects the diversity of P. falciparum infections. The
number of clones and parasite negativity predicted a lower risk of
malaria only in previously untreated children, which suggests that
continuous exposure and persistent infections are important for
maintenance of malaria immunity. Genotyping of P. falciparum
infections was a useful tool to more in depth study the effect of
different drug regimes for seasonal IPT on malaria exposure and
morbidity.
Figure 4. Kaplan Meier estimate (unadjusted) of time to subsequent clinical episode (fever and any P. falciparum) in 1856
asymptomatic children; a) placebo, b) SP bimonthly c) AS+AQ bimonthly and d) AS+AQ monthly. In the AS+AQ monthly group no
children with parasites at the survey after ended intervention developed clinical malaria.
doi:10.1371/journal.pone.0013649.g004
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